Baricitinib vs Pembrolizumab

Baricitinib vs Pembrolizumab: Overview

This comparison examines the pharmacological differences between Baricitinib and Pembrolizumab.

Mechanism of Action

Baricitinib: Selective JAK1 and JAK2 inhibitor blocking cytokine signaling involved in inflammation.

Pembrolizumab: Anti-PD-1 monoclonal antibody restoring anti-tumor immunity.

Pharmacokinetics

Half-life: Baricitinib — 12 hours; Pembrolizumab — 26 days.

Chemical Properties

Molecular Formula: Baricitinib — C16H17N7O2S.

Molecular Weight: Baricitinib — 371.4170 g/mol.

Type: Baricitinib — Small molecule; Pembrolizumab — Antibody.